GC Cell
Tuesday, June 04, 2024
Cell and Gene Therapy and Genome Editing
Company Presentation Theater 2
GC Cell is at the forefront of the global cell therapy market as a biotech solution pioneer. Our autologous CIK cell product, "Immuncell-LC,"has received approval from the Korean Ministry of Food and Drug Safety (MFDS) as an adjuvant therapy for Hepatocellular Carcinoma. Beyond our approved product, we are actively advancing the development of allogeneic naive NK cell and CAR NK cell products, currently in clinical trials in both the United States and Korea.
Company Website:
https://www.gccell.com/en/main.do
Lead Product in Development:
Immuncell-LC, CIK therapy (Marketed for adjuvant therapy in HCC)
GCC4001, Cord Blood Derived NK Cell Therapy ( Phase 1 & 2 clinical trials for r/r lymphoma)
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Immuncell-LC
Cord Blood Derived NK (GCC4001)
HER2 CAR-NK (GCC2003)
CD5 CAR-NK (GCC2005)
CD19 CAR-NK (GCC2004)
Exchange
KOSDAQ
Ticker
144510
Company HQ City
Yongin-si
Company HQ State
Gyeonggi-do
Company HQ Country
Korea, Republic of
CEO/Top Company Official
James Park
Development Phase of Primary Product
Multiple Products in Market
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())